Pair page
Gonadorelin with Testagen
Mechanism-tag overlap and published literature for Gonadorelin and Testagen, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
gnrhsynthetic-gonadotropin-releasing-hormone
khavinson-testicular-bioregulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Gonadorelin and Testagen have published these mechanism-level observations. Not a co-administration recommendation.
Gonadorelin (GnRH analog) stimulates pituitary LH/FSH release — acting upstream of the testes. Testagen is proposed to act at the testicular gene-expression level. Mechanistically complementary, both supporting endogenous testosterone production without exogenous T. No controlled combination data.
Quick facts
Gonadorelin
Testagen
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Gonadorelin | Kohn TP, Louis MR, Pickett SM, Lindgren MC, Kohn JR, Pastuszak AW, Lipshultz LI. Effects of subcutaneous gonadotropin-releasing hormone administration on serum hormonal concentrations, semen parameters, and sperm retrieval in men with hypogonadism undergoing testosterone therapy… PMID 33705811 | human study |
| 2002 | Gonadorelin | Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(9):4128-4136. PMID: 12213860. PMID 12213860 | human study |
| 1994 | Gonadorelin | Filicori M, Flamigni C, Dellai P, Cognigni G, Michelacci L, Arnone R, Sambataro M, Falbo A. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab. 1994;79(4):1215-1220. PMID: 7962300. PMID 7962300 | human study |
| 1986 | Gonadorelin | Santoro N, Filicori M, Crowley WF. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev. 1986;7(1):11-23. PMID: 3082643. (Pulsatile GnRH therapy review.) PMID 3082643 | human study |
| 1982 | Gonadorelin | Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307(20):1237-1241. PMID: 6811941. (Pivotal pulsatile GnRH clinical paper.) PMID 6811941 | human study |
| 1971 | Gonadorelin | Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43(6):1334-1339. PMID: 4936338. (GnRH primary structure.) PMID 4936338 | preclinical, in vivo |
| 1971 | Gonadorelin | Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393-399. PMID: 4930263. (Schally GnRH isolation paper — Nobel Prize 1977.) PMID 4930263 | mechanism / discovery |
| 2026 | Gonadorelin | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (Gonadorelin banned in males under S2.2.) | regulatory / registry |
| — | Gonadorelin | FDA. Factrel (gonadorelin hydrochloride) Prescribing Information. FDA.gov. Wyeth Ayerst (discontinued). (Historical FDA approval reference.) | regulatory / registry |
| — | Gonadorelin | FDA. Lutrepulse / Lutrelef (gonadorelin acetate) Prescribing Information. FDA.gov. Ferring (discontinued). (Historical FDA pulsatile-pump approval.) | regulatory / registry |
| 2015 | Gonadorelin | Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. Asian J Androl. 2015;17(2):197-200. PMID: 25337841. (TRT fertility preservation review — HCG context.) PMID 25337841 | research article |
| 2014 | Gonadorelin | Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271-1279. PMID: 24636400. (Context for modern HPG preservation strategies.) PMID 24636400 | research article |
| 2012 | Testagen | Khavinson VK, Solovyev AY, Zhilinskiy DV, Shataeva LK, Vanyushin BF. Effect of peptides on the proliferative activity of cells of rat pituitary anterior lobe in organotypic culture. Bull Exp Biol Med. 2012;153(1):148-151. PMID: 22808512. PMID 22808512 | preclinical, in vivo |
| 2011 | Testagen | Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID: 221… PMID 22118470 | preclinical, in vitro |
| 2021 | Testagen | Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of cell differentiation, gene expression, and protein synthesis. Bull Exp Biol Med. 2021;170(5):707-711. (Review including testicular and other tissue-specific peptides.) | mechanism / discovery |
| 2003 | Testagen | Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937678. (Representative Khavinson-group mechanistic paper; establishes the methodological style.) PMID 12937678 | mechanism / discovery |
| 2002 | Testagen | Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906. (Foundational review of the Khavinson peptide bioregulator framework.) PMID 12374906 | review |
| 2026 | Testagen | ClinicalTrials.gov. Search: "Testagen" or "KEDG peptide" returns no registered trials. Accessed April 2026. | regulatory / registry |
| 2025 | Testagen | FDA. Bulk Drug Substances Nominated for Use in Compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.gov. Updated 2025–2026 (Testagen / KEDG not listed). | regulatory / registry |
| 2025 | Testagen | WADA. 2025 Prohibited List. World Anti-Doping Agency. (Testagen not specifically named.) | regulatory / registry |
| 2020 | Testagen | Khavinson VK, Linkova NS, Ashapkin VV, Ryzhak GA. Peptide Regulation of Aging: 40 Years of Research. Bull Exp Biol Med. 2020;170(2):190-193. PMID: 33263832. PMID 33263832 | bioregulator literature |
| 2020 | Testagen | Khavinson VK. Peptide drugs: their role in fundamental and applied medicine. Advances in Gerontology. 2020 Khavinson group series. | bioregulator literature |
| 2011 | Testagen | Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up study. Bull Exp Biol Med. 2011;151(3):366-369. PMID: 22451891. PMID 22451891 | bioregulator literature |
| 2010 | Testagen | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19415510. PMID 19415510 | bioregulator literature |
Related pair pages
More research context
Frequently asked
Have Gonadorelin and Testagen been studied together?
Researchers have published mechanistic-level co-administration discussion of Gonadorelin and Testagen. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Gonadorelin and Testagen share?
Gonadorelin and Testagen do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Gonadorelin and Testagen?
Gonadorelin: Historical approval (Factrel, Lutrepulse); compounded off-label currently. Testagen: Not approved; research-only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Gonadorelin and Testagen?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Gonadorelin profile and the Testagen profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026